Roche's ROS1+ can­cer drug gets FDA green­light for Foun­da­tion Med­i­cine's com­pan­ion di­ag­nos­tic

More than four years af­ter Roche bought Igny­ta, ac­quir­ing a drug — en­trec­tinib — that scored FDA ap­proval about 18 months lat­er, Roche now has a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.